Pharmacokinetics and brain distribution studies of perphenazine-loaded solid lipid nanoparticles
Drug Development and Industrial Pharmacy, 2021•Taylor & Francis
Background Perphenazine (PPZ) is a typical antipsychotic that is mainly administrated for
the treatment of schizophrenia. Due to its highly lipophilic nature and extensive hepatic first-
pass metabolism, its oral bioavailability is low (40%). Objective The novel nanocarriers like
solid lipid nanoparticles (SLN) have been reported to be highly effective for improving the
therapeutic effect of drugs. Therefore the main scope of the present investigation was the
evaluation of in vivo characteristics of PPZ-SLN in terms of pharmacokinetic parameters and …
the treatment of schizophrenia. Due to its highly lipophilic nature and extensive hepatic first-
pass metabolism, its oral bioavailability is low (40%). Objective The novel nanocarriers like
solid lipid nanoparticles (SLN) have been reported to be highly effective for improving the
therapeutic effect of drugs. Therefore the main scope of the present investigation was the
evaluation of in vivo characteristics of PPZ-SLN in terms of pharmacokinetic parameters and …
Background
Perphenazine (PPZ) is a typical antipsychotic that is mainly administrated for the treatment of schizophrenia. Due to its highly lipophilic nature and extensive hepatic first-pass metabolism, its oral bioavailability is low (40%).
Objective
The novel nanocarriers like solid lipid nanoparticles (SLN) have been reported to be highly effective for improving the therapeutic effect of drugs. Therefore the main scope of the present investigation was the evaluation of in vivo characteristics of PPZ-SLN in terms of pharmacokinetic parameters and brain distribution.
Methods
The PPZ-SLN was prepared by the solvent-emulsification and evaporation method. The storage stability of PPZ-SLN and empty SLN powders was studied for 3 months. In vivo pharmacokinetic studies and brain distribution evaluations were performed following a single oral dose administration of PPZ and PPZ-SLN suspensions on male Wistar rats. An HPLC method was established and validated for the quantitative determination of PPZ in plasma and brain samples.
Results
The storage stability studies revealed the good storage stability of the both PPZ-SLN and empty SLN at 4 °C. Compared to PPZ suspension, the relative bioavailability and the brain distribution of PPZ-SLN were increased up to 2-fold and 16-fold, respectively. Mean residence time (MRT) and half-life (t1/2) of PPZ-SLN were significantly (p value < 0.01) increased in both plasma and brain homogenate compared to PPZ suspension.
Conclusion
The significant improvement in the pharmacokinetic properties of PPZ following one oral dose indicates that SLN is a promising drug delivery system for PPZ and shows a high potential for successful brain delivery of this antipsychotic.
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果